ACRS Reports $1.2M Revenue, $0.01 EPS, +150% YoY, Launches Phase 2b ATI-052 Asthma Trial, $200M Cash Runway Through 2028
Aclaris Therapeutics, Inc. · PHARMACEUTICAL PREPARATIONS · Now $4.34
-9.5% in 7d after detection
Post-detection moves
1h
—
1d
+1.4%
3d
+0.4%
7d
-9.5%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS